C90.32
Solitary plasmacytoma in relapse
Clinical Classification Guidelines
Medical Intelligence & Overview
Solitary plasmacytoma in relapse refers to a localized collection of abnormal plasma cells that has returned after previous treatment. Plasma cells are a type of white blood cell involved in producing antibodies. When these cells grow excessively in a specific area, it results in a plasmacytoma. The term 'relapse' indicates that the disease has recurred after initial treatment, often requiring further medical attention to manage the condition effectively.
Causes & Symptoms
Clinical Causes: Previous plasmacytoma which was not entirely eradicated Genetic mutations leading to abnormal plasma cell growth Age-related immune system changes Underlying conditions that compromise immune defenses
Key Symptoms: Localized pain or swelling at the site of the plasmacytoma Persistent discomfort or tenderness Possible neurological symptoms if the tumor presses on nerves In some cases, no noticeable symptoms until the tumor grows large
Diagnostic & Treatment
Diagnosis Path: Medical history assessment and physical examination Imaging tests such as MRI, CT scans, or X-rays to locate the tumor Biopsy of the affected tissue to analyze plasma cell characteristics Blood and urine tests to check for abnormal proteins related to plasma cell proliferation Bone marrow examination if systemic disease is suspected
Treatment Protocols: Radiation therapy to target and destroy local tumor cells Surgical removal if the plasmacytoma is accessible and localized Chemotherapy in cases where the tumor recurs or progresses Stem cell transplantation may be considered for advanced or recurrent cases Regular follow-up to monitor for further relapse or progression
Clinical Advice & FAQs
Billing Guidance
Is C90.32 a billable ICD-10 code?
Yes, C90.32 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C90.32?
Clinical documentation must specify the nature of Solitary plasmacytoma in relapse and any associated comorbidities for accurate reporting.
Cite this Clinical Reference